ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Non-Hodgkin Lymphoma trials near Pittsburgh, PA, USA:

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Pittsburgh, Pennsylvania, United States and 39 other locations

efficacy of combination Golcadomide and nivolumab in patients with non-Hodgkin lymphoma (NHL) who have experienced refract...

Not yet enrolling
Non Hodgkin Lymphoma
Drug: GOLCADOMIDE
Drug: Nivolumab

Phase 1, Phase 2

Natalie Galanina

Pittsburgh, Pennsylvania, United States

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Pittsburgh, Pennsylvania, United States and 56 other locations

receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non...

Enrolling
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Biological: JNJ-90014496

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 25 other locations

bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or mo...

Enrolling
B-cell Non Hodgkin Lymphoma
Follicular Lymphoma
Drug: AZD0486 IV

Phase 1

AstraZeneca
AstraZeneca

Pittsburgh, Pennsylvania, United States and 28 other locations

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

Enrolling
T-cell Lymphoma
Cutaneous T-cell Lymphoma
Drug: Fenretinide

Phase 1

SciTech Development

Pittsburgh, Pennsylvania, United States and 8 other locations

with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma
Drug: Polatuzumab vedotin
Drug: Tocilizumab

Phase 1, Phase 2

Roche
Roche

Pittsburgh, Pennsylvania, United States and 28 other locations

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Active, not recruiting
Non-Hodgkin's Lymphoma
Drug: Glofitamab
Drug: Obinutuzumab

Phase 1, Phase 2

Roche
Roche

Pittsburgh, Pennsylvania, United States and 32 other locations

Locations recently updated

monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...

Enrolling
B-cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Drug: AZD0486

Phase 2

AstraZeneca
AstraZeneca

Pittsburgh, Pennsylvania, United States and 84 other locations

This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, eith...

Active, not recruiting
Non-Hodgkin Lymphoma (NHL)
Follicular Lymphoma (FL)
Drug: Tazemetostat

Phase 1, Phase 2

Epizyme

Pittsburgh, Pennsylvania, United States and 33 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems